WO2024033896 - OLIGONUCLEOTIDES TARGETING INDOLEAMINE 2,3-DIOXYGENASE AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2024/033896
Publication Date
15.02.2024
International Application No.
PCT/IB2023/058154
International Filing Date
11.08.2023
Title **
[English]
OLIGONUCLEOTIDES TARGETING INDOLEAMINE 2,3-DIOXYGENASE AND USES THEREOF
[French]
OLIGONUCLÉOTIDES CIBLANT L'INDOLÉAMINE 2, 3-DIOXYGÉNASE ET LEURS UTILISATIONS
Applicants **
BIORCHESTRA CO., LTD.
Inventors
RYU, Jin-Hyeob
KWON, Mincheol
Priority Data
63/371,343
12.08.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5146 | |
| EPO | Filing, Examination, Granting | 101892 | |
| Japan | Filing, Examination, Granting | 4944 | |
| South Korea | Filing, Examination, Granting | 5533 | |
| USA | Filing, Examination, Granting | 41340 |
Total:
158,855
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to small interfering RNAs, which target IDO1 mRNA in a cell, leading to reduced expression of IDO1 protein. Reduction of IDO1 protein expression is beneficial for the treatment of certain medical disorders, e.g., a cancer or a neuronal disease.[French]
La présente invention concerne de petits ARN interférents, qui ciblent l'ARNm IDO1 dans une cellule, conduisant à une expression réduite de la protéine IDO1. La réduction de l'expression de la protéine IDO1 est bénéfique pour le traitement de certains troubles médicaux, par exemple, un cancer ou une maladie neuronale.